Source comparison
Melanotan-1 vs Melanotan-2: Research Peptide Comparison
The table below summarises the structural, pharmacological, and regulatory differences that define the Melanotan-1 vs Melanotan-2 comparison for research applications. Structure Linear 13-amino-acid peptide (Nle⁴-D-Phe⁷-α-MSH) Cyclic 7-amino-acid peptide (Ac-N
This comparison does not assign a generated winner or score.
- The table below summarises the structural, pharmacological, and regulatory differences that define the Melanotan-1 vs Melanotan-2 comparison for research applications.
- Structure
- Linear 13-amino-acid peptide (Nle⁴-D-Phe⁷-α-MSH)
- Cyclic 7-amino-acid peptide (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂)
- Cyclic structure confers Melanotan-2's broad receptor activity; linear structure limits Melanotan-1 to MC1 selectivity
- Receptor Selectivity
- MC1-selective (nanomolar affinity); minimal MC3/MC4/MC5 activity
- Non-selective (MC1, MC3, MC4, MC5 agonist)
- Melanotan-1's selectivity eliminates systemic side effects; Melanotan-2's promiscuity enables metabolic research but introduces cardiovascular risk
- Half-Life
- ~33 minutes (IV); 60-day sustained release (implant)
- ~1 hour (subcutaneous); tissue accumulation extends activity
- Depot formulations make Melanotan-1 viable for clinical use; Melanotan-2's accumulation complicates washout
- Melanogenesis Onset
- 3–5 days (implant); 7–10 days (daily injection)
- 5–7 days (daily injection at 0.025mg/kg)
- Comparable onset when dose-adjusted; Melanotan-2 requires lower per-dose amounts due to higher affinity
- Adverse Events
- Nausea (10–15%), injection site reactions; rare nevi darkening
- Hypertension (30–40%), flushing, nausea, spontaneous erections
- Melanotan-1's FDA approval reflects clean safety profile; Melanotan-2's cardiovascular effects limit human research
- Regulatory Status
- FDA-approved (Scenesse, 2019) for erythropoietic protoporphyria
- Not FDA-approved; classified as unapproved drug with safety warnings
- Only Melanotan-1 has regulatory clearance; Melanotan-2 remains experimental
- Typical Research Dose
- 0.016–0.020mg/kg subcutaneous (daily) or 16mg implant (60-day)
- 0.01–0.025mg/kg subcutaneous (loading); 0.005–0.01mg/kg (maintenance)
- Lower Melanotan-2 doses reflect higher potency; both achieve melanogenesis at therapeutic ranges
- This comparison establishes that Melanotan-1 vs Melanotan-2 is not a question of equivalence with dose adjustment. Receptor selectivity fundamentally alters the experimental and safety landscape. Researchers requiring isolated melanogenesis without systemic confounders select Melanotan-1; those investigating melanocortin's role in appetite, metabolism, or neuroprotection may select Melanotan-2 with appropriate cardiovascular monitoring.